Tamoxifen, also known as ICI 46474, is an antagonist of the estrogen receptor in breast tissue via its active metabolite, 4-hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a selective estrogen-receptor modulator. Tamoxifen is the usual endocrine (anti-estrogen) therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting.
Estrogen/progestogen Receptor Inhibitors Related Products:
Fulvestrant; Raloxifene hydrochloride; Lasofoxifene Tartrate; Brilanestrant; Tamoxifen citrate; Dienogest; Drospirenone; Ulipristal acetate; Megestrol Acetate; Pregnenolone; Estriol; Estrone; Bazedoxifene Acetate; Endoxifen HCl; Ospemifene; AZD9496; Desogestrel